go to contents go to 1depth menu
Aiming to be a global drug maker


CJ HealthCare Corp. studies various fields.

ONCOLOGY PROJECT CJ-15314 CJ-14199 Tegoprazan
NCE Etc. Immuno-
alcoholic steatohepatitis
Gastroesophageal reflux disease

CJ HealthCare Corp. is expanding its pipeline by focusing on digestive disorders, anti-cancer, and immune diseases that have high unmet needs in the market.
Based on its experience and know-how in the development of fixed dose combination IMDs, CJ HealthCare Corp. is developing various new drugs, such as the gastroesophageal reflux disease treatment 'Tegoprazan'. CJ HealthCare Corp. is accelerating the development of promising new drugs and expanding its R&D network by continuously carrying out "open innovation" with excellent R&D venture companies in Korea, Japan, the U.S. and Europe.